Menu
Brit Mollenhauer is a neurologist with over 10 years clinical expertise in Parkinson’s disease and movement disorders.
She also has a degree in neurochemistry. After her studies in neuroscience at Harvard Medical School, Cambridge, USA she became head of translational research at the Paracelsus-Elena Klinik (PEKK), which is the largest hospital for movement disorders in Germany with 120 beds and more than 3000 patients per year.
Dr.Brit Mollenhauer has developed a study center for clinical trials and translational research with close collaborations with the Michael J. Fox Foundation for Parkinson’s Research; the clinic is one of the 7 European recruitment centers for the PPMI study.
The following 4 research products highlight our experience and qualifications as a Research Center of Excellence
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
Our flagship α-synuclein SAA, SYNTap®, is getting a makeover.
Effective September 9, 2024, SYNTap will be
And stay tuned for the SAAmplify family of panels, coming soon!
